Syndax Pharmaceuticals, Inc. (SNDX) Year-over-year earnings per share growth for the last twelve months

Graphic logo of Syndax Pharmaceuticals, Inc. (SNDX)

Syndax Pharmaceuticals (SNDX) faces significant risk concentration due to its high dependence on regulatory approvals. The quarterly EPS growth rate reflects the performance of management, whose transparency regarding the FDA and expertise in commercializing inhibitors warrant close attention. Revenues are based on licenses and grants for target molecules. The current value of the parameter is 21.40, confirming the sensitivity of profits to external factors.

Syndax Pharmaceuticals, Inc. (SNDX) - Year-over-year earnings per share growth for the last 12 months from 07/04/2022 to 11/16/2026

Analytical breakdowns for Syndax Pharmaceuticals

- market value and analyst target forecast:
- market capitalization details:
Summary company analysis:Syndax Pharmaceuticals - SNDX
Finished products of Syndax Pharmaceuticals

The fundamental attractiveness of Syndax Pharmaceuticals (SNDX) is determined by its ability to generate net earnings per share. The quarterly EPS trend reflects real growth in profitability, stripping speculative noise from the quotes. This metric measures the efficiency of business capitalization, allowing investors to distinguish market euphoria from actual financial progress. The stability of this indicator is supported by minimal turnover among key biochemists. The targeted hiring of commercialization experts should transform scientific achievements into sustainable profit growth.

Key competitors

tgtherapeutics.com (TGTX) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Arcellx Therapeutics (ACLX)|Year-over-year earnings per share growth for the last twelve months Disc Medicine Inc|Earnings per share growth in annualized terms for the last twelve months Kura Oncology, Inc. KURA|Quarterly EPS earnings growth ADCT|Foghorn Therapeutics Inc. - Year-over-year earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months vorbio.com VOR|NKTX: Year-over-year earnings per share growth for the last 12 months|COEP - Year-over-year earnings per share growth for the last twelve months|Actinium Pharmaceuticals, Inc. (ATNM) - Year-over-year net earnings per share growth for the last 12 months|ESLA (Estrella Immunopharma) - Year-over-year net earnings per share growth for the last 12 months|CASI - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Marker Bio|Quarterly EPS earnings growth IN8bio, Inc.|Year-over-year earnings per share growth for the last twelve months Eterna Therapeutics Inc (ERNA)|Year-over-year net earnings per share change for the last twelve months gtbiopharma.com|Quarterly EPS earnings growth APTO (Aptose Biosciences)|Quarterly EPS earnings growth Bio-Path BPTH|MEI Pharma Inc - Quarterly EPS earnings growth|VINC (Vincerx Pharma Inc.) - Year-over-year earnings per share growth for the last 12 months